Brief: Milestone Pharmaceuticals Announces Etripamil Afib-Rvr Study Is Selected For Featured Science Presentation At The American Heart Association Scientific Sessions 2023
27/09/2023 12:05
Milestone Pharmaceuticals Inc MIST.O :
* MILESTONE PHARMACEUTICALS ANNOUNCES ETRIPAMIL AFIB-RVR
STUDY IS
SELECTED FOR FEATURED SCIENCE PRESENTATION AT THE AMERICAN HEART
ASSOCIATION SCIENTIFIC SESSIONS 2023
Source text for Eikon: ID:nCNW3LvlRa
Further company coverage: MIST.O
Recent news on Milestone Pharmaceuticals
See all newsBrief: Milestone Pharmaceuticals Announces First European Study Participant Enrolled In Revera-301 Phase 3 Clinical Trial
Brief: Milestone Pharmaceuticals Says NMPA Approval Triggers $2 Mln Milestone Payment To The Co
Milestone Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Canada's Milestone Pharma misses Q2 product revenue expectations
Milestone Pharmaceuticals Inc expected to post a loss of 19 cents a share - Earnings Preview